# Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

> **NCT02539459** · PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Sporadic Angiomyolipomas (AMLs)

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02539459
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-23
- **Primary completion:** 2018-08-20
- **Final completion:** 2018-08-20
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Extreme toxicity, met toxicity stopping rules
- **Last updated:** 2022-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02539459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02539459, "Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02539459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*